Assessment of a rapid liquid-based cytology method for measuring sputum cell counts

Differential sputum cell counting is not widely available despite proven clinical utility in the management of asthma. We compared eosinophil counts obtained using liquid-based cytology (LBC), a routine histopathological processing method, and the current standard method. Eosinophil counts obtained using LBC were a strong predictor of sputum eosinophilia ($\geq 3\%$) determined by the standard method suggesting LBC could be used in the management of asthma.

BACKGROUND

Differential cell counts (DCCs) of induced sputum samples have been shown to be useful in the management of patients with moderate-to-severe asthma¹ and in the diagnosis of eosinophilic bronchitis.² Unfortunately, sputum processing is time consuming,³ taking approximately 4 hours, and a meta-analysis concluded that its routine use could not be justified due to the technical expertise required.⁴ We aimed to establish whether a simplified method using routine liquid-based cytology (LBC), used in histopathology laboratories throughout the National Health Service (NHS), could provide similar results.

METHOD

Subjects with asthma or chronic cough presenting to an outpatient respiratory clinic who were willing to take part in the study were consented and spirometry performed. Sputum samples were induced

using hypertonic saline as previously described,³ following which sputum plugs were isolated, weighed and divided into two equal portions.

The first sample was processed as described previously,³ and the resultant slide counted by a trained research scientist. Cell counts were later reviewed by a second scientist blinded to the results and any discrepancies in counts were resolved by reassessment by both scientists.

For the LBC method, sputum samples were manually mixed in 10 mL CytoRich Red (CRR) solution with a pipette. The mixture was shaken on an Ika-Vibrax-VXR shaker at 1000 rpm for 30 min to homogenise the sample and then centrifuged at 780 g for 5 min. The resultant pellets were resuspended in 1.5 mL CRR and 0.75 mL aliquots were deposited into settling chambers positioned on coated slides for a minimum of 10 min. Any excess fluid was extracted from the chambers using a pipette. The chambers were then removed and the slides fixed and stained using the Papanicolaou method. Eosinophils in 100 high-power fields ($\times 400$) were counted and averaged for each slide by a single consultant histopathologist (IS) blinded to the

Figure 1 Empirical receiver operator characteristic (ROC) curve showing the sensitivity (%) and 100-specificity (%) of liquid-based cytology -derived eosinophil count (eosinophils per high-power field) to identify a sputum differential eosinophil count of $\geq 3\%$ for all samples and *after exclusion of samples with $\leq 50\%$ viability and/or $\geq 20\%$ squamous contamination.

Table 1 Sensitivity and specificity values for each liquid-based cytology (LBC) grade to identify a differential cell count sputum eosinophil count of $\geq 3\%$ for all slides

LBC grade (eos/hpf)	Sensitivity %	95% CI (%)	Specificity %	95% CI (%)	PPV %	NPV %
1 (1–2)	100	78.2 to 100	20	7.7 to 38.6	37.5	100
2 (3–4)	93.3	68.1 to 99.8	56.7	37.4 to 74.5	51.9	95.4
3 (5–10)	93.3	68.1 to 99.8	70	50.6 to 85.3	60.9	95.5
4 (>10)	66.7 (83.3*)	38.4 to 88.2	96.7	82.8 to 99.9	90.9	85.3 (93.1*)

*Values for sensitivity and NPV after excluding slides with low viability/squamous contamination (n=6). eos/hpf, eosinophils per high-power field; NPV, negative predictive value; PPV, positive predictive value.

DCC results. Each slide was graded on an ordinal scale of 0–4 based on the approximate number of eosinophils per high-power field (eos/hpf), where 0=0 eos/hpf, 1=1–2 eos/hpf, 2=3–4 eos/hpf, 3=5–10 eos/hpf and 4= >10 eos/hpf.

Data were entered into GraphPad Prism. Empirical receiver operator characteristic (ROC) curves and sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for each LBC 'grade' to identify a sputum eosinophil count of $\geq 3\%$ ¹ were generated. This analysis was repeated with exclusion of samples with $\leq 50\%$ viability and/or $\geq 20\%$ squamous cell contamination for comparative purposes with previous studies investigating the interobserver agreement of DCCs.⁵

RESULTS

Demographic and lung function data are available in the online supplementary data. Of 55 patients, 6 produced samples of insufficient volume to process by either technique and 4 samples were uncountable by both methods, leaving 45 pairs of slides available for counting. Four slides were identified by DCC with $\leq 50\%$ viability and two slides had $\geq 20\%$ squamous contamination, leaving 39 pairs of slides for counting in the 'exclusion set'. The empirical ROC curve to assess the utility of the LBC-based method to identify a sputum eosinophil count of $\geq 3\%$ had an area under the curve of 0.90 ($p<0.001$) (figure 1), which increased to 0.95 ($p<0.001$) upon excluding slides with low viability or significant squamous contamination. The cut-point with the highest combined set of values for sensitivity, specificity, PPV and NPV for identifying a sputum eosinophil count of $\geq 3\%$ was >10 eos/hpf, as shown in table 1. Processing of sputum took approximately 1 hour with LBC compared with approximately 4 hours using the current cytospin and DCC technique. Examples of slides produced by both methods are shown in the online supplementary data.

DISCUSSION

Our results indicate that a cut-off point of >10 eos/hpf from the LBC technique has a high PPV and NPV to identify patients with a sputum differential eosinophil count of $\geq$ or $<3\%$. This is important in asthma management because this value is associated with increased risk of exacerbations and can be modified with additional oral or inhaled corticosteroids.¹

Sputum DCCs have demonstrated utility in guiding treatment decisions in patients with more severe asthma,¹ but the DCC technique has not been widely adopted into clinical practice because of the time and technical expertise required to perform it. Any novel method of assessing sputum eosinophilia must therefore be compared with DCC. However, differences in results do not necessarily mean the DCC method is superior to the LBC approach. First, it cannot be excluded that differences in eosinophil counts produced by the two methods were due to heterogeneous distribution of the cellular portion of the sample, resulting in a higher eosinophil concentration in one part of the sample than the other. Second, the DCC technique is not subject to the formal quality control procedures in place for laboratory investigations performed in the NHS. It remains possible that LBC with an eosinophil count performed by a consultant histopathologist is more accurate than research scientists performing DCC. LBC also has some practical advantages: (1) samples do not have to be processed on the day of collection as for DCC⁶ because CRR acts as a mucolytic and a fixative and (2) the LBC technique is less time intensive, making it more suitable for use in NHS histopathology departments.

The next step is to demonstrate that these results can be reproduced at other centres and that treatment decisions based on LBC are beneficial in terms of asthma outcomes as has been shown for DCCs.¹ These studies should include blood eosinophil counts, which are more easily obtained and have been demonstrated to be a good predictor of sputum eosinophilia in subjects undergoing COPD exacerbations⁷ and a moderate predictor of sputum eosinophilia in asthma.⁸ The reliability of LBC eosinophil counts from mucopurulent sputum samples from subjects with COPD also needs to be assessed.

M J Martin,¹ H Lee,¹ G Meakin,¹ A Green,¹
R L Simms,¹ C Reynolds,¹ S Winters,² D E Shaw,¹
I Soomro,² T W Harrison¹

¹The Asthma Centre, Nottingham Respiratory Research Unit, University of Nottingham, Nottingham City Hospital, Nottingham, UK

²Department of Cellular Pathology, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, UK

Correspondence to Professor Tim Harrison, Room B23, Clinical Sciences Building, Nottingham City Hospital, Hucknall Rd, Nottingham NG5 1PB, UK; tim.harrison@nottingham.ac.uk

Contributors TWH had full access to all the data in the study, is the guarantor of the content of the manuscript, including the data and analysis, and takes responsibility for the integrity of the data and the accuracy of the data analysis, including any adverse effects. TWH and IS designed the study. HL, GM, AG, RLS, CR and SW contributed substantially to data collection. Sputum samples were processed by HL, GM, AG, RLS and SW and counted by HL, AG, RLS and IS. MJM, DES and TWH contributed substantially to data analysis and interpretation and the writing of the manuscript.

Competing interests None declared.

Ethics approval Nottingham Research Ethics Committee 1 (REC: 08/H0407/2).

Provenance and peer review Not commissioned; externally peer reviewed.

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/thoraxjnl-2016-208817>).

CrossMark

To cite Martin MJ, Lee H, Meakin G, *et al.* *Thorax* 2016;**71**:1163–1164.

Received 25 April 2016

Revised 4 July 2016

Accepted 6 July 2016

Published Online First 08 August 2016

Thorax 2016;**71**:1163–1164.

doi:10.1136/thoraxjnl-2016-208817

REFERENCES

- Green RH, Brightling CE, McKenna S, *et al.* Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. *Lancet* 2002;**360**:1715–21.
- Gibson PG, Dolovich J, Denburg J, *et al.* Chronic cough: eosinophilic bronchitis without asthma. *Lancet* 1989;**1**:1346–8.
- Pavord ID, Pizzichini MM, Pizzichini E, *et al.* The use of induced sputum to investigate airway inflammation. *Thorax* 1997;**52**: 498–501.
- Petsky HL, Cates CJ, Lasserson TJ, *et al.* A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). *Thorax* 2012;**67**:199–208.
- Ward R, Woltmann G, Wardlaw AJ, *et al.* Between-observer repeatability of sputum differential cell counts. Influence of cell viability and squamous cell contamination. *Clin Exp Allergy* 1999;**29**:248–52.
- Efthimiadis A, Jayaram L, Weston S, *et al.* Induced sputum: time from expectoration to processing. *Eur Respir J* 2002;**19**:706–8.
- Bafadhel M, McKenna S, Terry S, *et al.* Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. *Am J Respir Crit Care Med* 2011;**184**:662–71.
- Korevaar DA, Westerhof GA, Wang J, *et al.* Diagnostic accuracy of minimally invasive markers

for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. *Lancet Respir Med* 2015;**3**:290–300.